Oncology Overdrive

In this episode, host Shikha Jain, MD, speaks with Abiola Ibraheem, MD, about the role culture plays in improving global oncology, launching the Best of ASCO in Africa and more. •    Welcome to another exciting episode of Oncology Overdrive 1:34 •    About Ibraheem 1:42 •    The interview 3:02 •    How did you get where you are today?  3:28 •    Can you tell me more about Aortic Africa and your role within the organization? 5:41 •    What are some challenges you have encountered in doing this work, both locally and internationally? 7:33 •    How have you navigated the nuances of global oncology in other countries?  9:51 •    Did you get any pushback when you decided to create these global relationships and inroads? How did you navigate receiving different perspectives on your work? 12:10 •    What are you hoping to achieve with these efforts in global oncology? 16:28 •    Where did the idea for a Best of ASCO Africa come from, and what do you hope to achieve with the event? 17:41 •    Jain and Ibraheem on the importance of providing other countries with tools to implement and drive global change. 22:54 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 27:29 •    How to contact Ibraheem 28:09 •    Thanks for listening 29:07 Abiola Ibraheem, MD, is a board-certified medical oncologist and assistant professor at the University of Illinois Chicago. Her journey in medicine began in Nigeria, where she earned her MBBS degree from Olabisi Onabanjo University. She then completed her internal medicine residency at Morehouse School of Medicine, focusing on racial health care disparities. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Ibraheem can be reached via email at abiolai@uic.edu. Learn more about Best of ASCO Africa, as well as how to sign up for in-person or virtual attendance, happening June 27 & 28 in Addis Abba, Ethiopia. Disclosures: Jain and Ibraheem report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Nadine Spring, PhD, about the importance of DEI in clinical care, driving positive social change forward and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Spring 0:20 •    The interview 1:00 •    Tell me about the journey that got you to where you are today?  1:18 •    Can you tell me more about Adtalem Global Education and your role there? 5:11 •    Why does diversity and equitable representation in clinical trials and care matter? 6:23 •    What is SpringWell360, and what do you hope to achieve with the work you are doing through this organization?  8:28 •    Do you think that current funding challenges will impact these initiatives over the next few years? 11:37 •    Do you feel like you will have to re-imagine or modify how you describe the work you are doing to help people understand its impact? 12:11 •    How do you suggest clinicians and institution leaders get involved in raising awareness and increasing diversity in clinical trials? 12:48 •    What do you say to people who are doing this work and are getting frustrated or burnt out? How do you keep them motivated? 16:37 •    What keeps you motivated to continue this work? 17:56 •    When you talk to people about clinical trials, how do you address patients' mistrust or fear of the unknown?  19:04 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 23:58 •    How to contact Spring 25:15 •    Thanks for listening 25:59 Nadine Spring, PhD, has spent her career fighting for more inclusive and diverse representation in clinical research. She is a recognized leader in advancing health equity, particularly through her work at SpringWell360, which advocates for the inclusion of underserved populations in clinical trials.  We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Spring can be reached at www.springwell360.com or via email nadine@springwell360.com. Disclosures: Jain and Spring report no relevant financial disclosures. 

In this special crossover episode with Physicianary, guest Navin Goyal, MD, and Physicianary host, Hansa Bhargava, MD, discuss side gigs in the health care space, encourage physicians to explore their fields of interest and talk about his book, Physician Underdog. •    Intro 0:28 •    Navin Goyal, MD 0:35 •    You have done a lot to help Medicaid patients with your venture capital group, OFFOR Health. Can you tell us about that? 1:25 •    What was the driver of your venture capital group? Was it access to care? 3:21 •    Tell us about your interest in health equity and access to care? What happened next. 6:28 •    Tell us about your book, Physician Underdog. Did the book come before, during or after your journey with your venture capital group? 7:55 •    What is your advice to physicians and health care workers who feel burnt out and unfulfilled in their career path? 11:54 •    Bhargava and Goyal discuss change and adapting to changes in career paths. 14:57 •    Bhargava and Goyal discuss the difference between careers in health care and other professions that are likely to pursue new avenues. 16:42 •    There are plenty of physicians out there looking for side gigs. What is your advice to physicians and health care workers who want to explore other avenues and side gigs? 19:29 •    How do you do it all? 22:10 •    Thanks 24:42 Navin Goyal, MD, is a venture capitalist, entrepreneur, physician and author—driven by his passion for human-centered leadership. He is the co-founder and managing partner at LOUD Capital, specializing in early-stage investments in healthcare and technology startups. Goyal is also co-founder of OFFOR Health, a venture-backed startup that provides mobile anesthesia services for pediatric patients on Medicaid, and Beyond Physician, an online learning management platform and job marketplace to enable physicians to learn new skills, get contract work and grow their thought leadership. His journey and insights are captured in his book, Physician Underdog. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Follow Dr. Bhargava on X @hansabhargavaMD and on Instagram @doctorhansaMD. Follow Goyal on Instagram @navin.g.md, X @Navin_MD, Facebook and LinkedIn and visit his website: navingoyalmd.com. Disclosures: Bhargava and Goyal report no relevant financial disclosures.

In this episode, host Shikha Jain, MD, speaks with Kimberly Richardson about driving changes in patient advocacy efforts, the importance of including DEI in cancer research and clinical trials and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Richardson 0:20 •    The interview 1:15 •    How did you get to where you are today as such a leader and advocate?  1:56 •    Did you feel welcomed into this space when you started doing your advocacy work, or did you feel like it was an uphill battle? 5:12 •    Jain and Richardson on how physicians and patient advocates can come up with solutions that coincide with the transformation of what advocacy work has become. 8:23 •    What are the different ways people can be patient advocates?  10:59 •    Jain and Richardson on research advocacy and the power of the ripple effect when it comes to how this work impacts patients. 15:45 •    Jain and Richardson on how physician and patients can collaborate to overcome institutional challenges with timing of visits and quality of care. 19:11 •    Richardson and Jain on educating patients in underrepresented communities on research and policy changes that will lead to more diversity in clinical trials.  24:21 •    If you could look back one year from now, what do you hope your research grant accomplishes? 30:00 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 32:00 •    How to contact Richardson 32:33 •    Thanks for listening 33:27 Kimberly Richardson is a survivor of ovarian cancer and early stage, triple positive breast cancer. Kimberly has founded the Black Cancer Collaborative, a 501 (c)3 nonprofit organization that creates partnerships between Black cancer patients and the medical and scientific communities on issues of health equity, patient inclusion and clinical trials participation. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Richardson can be found on Bluesky under Black Cancer Collaborative and on LinkedIn. Disclosures: Jain and Richardson report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Anna Rathkopf about the mental and physical toll of cancer treatment and survivorship, using photography to connect with patients and caregivers and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Rathkopf 0:20 •    The interview 1:23 •    How did you get into storytelling through photography around your cancer diagnosis and your caregiver experience?  1:46 •    How did you navigate questions and challenges surrounding fertility during the first five years of your diagnosis? 4:07 •    On top of everything else going on in your life at the time, how did your decision to document your treatment become part of your plan? Why was it so important for you to do in that moment?  7:50 •    Did photography help you feel like you had some control in your life?  10:45 •    Overall, how did this impact your mental health along with your physical health?  11:17 •    What were you doing from a photojournalistic standpoint prior to your diagnosis? How did that prepare you for this next step in what you have created?  14:46 •    How did your partner's caregiving responsibilities incorporate into your photography?  16:48 •    Jain and Rathkopf on the sacrifices caregivers make.  19:53 •    If you had to give advice to someone going through the initial time after cancer diagnosis, caregiver or patient, what would you say you would do the same or differently?  21:29 •    What do you suggest loved ones do or say to help patients and caregivers?  24:49 •    What was the transition into survivorship like for you after the first five years? How did that change your mentality? 27:24 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 33:34 •    How to contact Rathkopf 34:20 •    Thanks for listening 35:22 Anna Rathkopf is an award-winning photographer whose work focuses on empathy, health, and identity. She is the author of HER2: The Diagnosed, The Caregiver, and Their Son, a poignant exploration of the realities of cancer under 50.  We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Rathkopf can be found on Instagram @rathkopfphotography. Purchase HER2: The Diagnosed, The Caregiver, and Their Son on Amazon or on the website www.rathkopf.com.  For more from the Rathkopfs: Check out photos and video from their installation at A(I) Brighter Tomorrow: Cancer and Beyond) exhibition at Montefiore Einstein through April 18, 2025. Disclosures: Jain and Rathkopf report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with ASH president, Belinda Avalos, MD, about the importance of DEI practices in medicine, leading molecular medicine developments and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Avalos 0:18 •    The interview 1:18 •    How did you know you know you wanted to be a hematologist and how did you end up in this space doing the work you're doing now?  1:47 •    Jain and Avalos on the innovations and patient relationships in the field of HemOnc that drive physician interest. 3:25 •    What drove your passion to get involved in DEI and equitable care in medicine? 5:08 •    Jain and Avalos on diversity in clinical trials.  7:48 •    Jain and Avalos on the importance of multidisciplinary approaches to patient care.  9:08 •    What do you see as the biggest barriers to driving change in this space? How can we actually make changes that will result in real-world transformation?  10:11 •    Tell me about the work that you do in the spaces of women in hematology and medicine.  11:25 •    What types of things should we be doing to drive gender equity changes in medicine?  13:40 •    Do you feel hopeful about where we are going with the changes being driven by societies like ASH?  15:24 •    What else excites you about hematology and the innovation in the field now?  17:02 •    What are the biggest transformations we are going to see in hematology over the next decade?  23:26 •    Where will you be focusing your time moving forward?  27:53 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 29:16 •    How to contact Avalos 30:15 •    Thanks for listening 30:44 Belinda R. Avalos, MD, is the American Society of Hematology 2025 president, and is a professor of medicine and a senior advisor to the president of Atrium Health Levine Cancer. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Avalos can be reached by contacting ASH at www.hematology.org.  Disclosures: Jain and Avalos report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Opyl co-founder Damon Rasheed about using machine learning to better predict clinical trial outcomes, handling ethical concerns surrounding AI in health care and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Rasheed 0:20 •    The interview 0:58 •    How did you end up in the AI-powered medicine and clinical trials?  1:48 •    What is Opyl, and what is TrialKey? 3:54 •    Is TrialKey predominantly based in Australia or is it available outside of Australia as well? 5:34 •    Can you explain how machine learning works in order to create these outcomes?  6:11 •    How do you see people utilizing this tool in the future based on what you have already seen?  8:30 •    How have others received this? What is the feedback you have gotten surrounding what people are excited and concerned about with this technology?  10:50 •    Does this type of product take into account the issue of diversity in clinical trials?  13:41 •    What's next for expanding Opyl and TrialKey?  14:27 •    What keeps you excited and motivated to continue working in this space?  15:28 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 19:35 •    How to contact Rasheed 20:16 •    Thanks for listening 20:54 Damon Rasheed is a serial entrepreneur recognized for his groundbreaking ventures and deep expertise in machine learning and big data. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Rasheed can be reached at opyl.ai or trialkey.ai.  Disclosures: Jain reports no relevant financial disclosures. Rasheed reports TrialKey is powered by Opyl Limited, which is a publicly listed company operating on the ASX.

In this special crossover episode of Oncology Overdrive, we bring you Healio coverage from the ASH Annual Meeting and Exhibition, as well as Healio's top headlines from the meeting. Gwen L. Nichols, MD, reviews a panel discussion on how hematologists and oncologists can best address patients' concerns as AI's role in medicine invariably expands. :24 Thomas G. Knight, MD, addresses financial toxicity for people with blood cancer. 6:29 Charles S. Abrams, MD, discusses results of the HIBISCUS trial and its implications for vaso-occlusive events. 16:30 Read the full coverage here: AI in hematology: ‘The good, the bad and the ugly' Mitigating financial toxicity 'better than any drug' for people with cancer Etavopivat could offer ‘great benefit' in sickle cell disease ASH recognizes Judith Kleinerman, MD, with Exemplary Service Award GLP-1s reduce thrombosis risk among people with diabetes, regardless of obesity We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Disclosures: Jain reports no financial disclosures. Abrams reports he is chair of the ASH Research Collaborative's Sickle Cell Disease Clinical Trials Network Oversight Committee. Knight reports no relevant financial disclosures. Nichols reports no relevant financial disclosures.

In this episode, host Shikha Jain, MD, speaks with David Gandara, MD, about how ctDNA and CAR-T cell therapies are transforming precision medicine, the importance of patient reported outcomes and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Gandara 0:19 •    The interview 1:02 •    Can you tell me a little more about what you are working on now? 1:25 •    How did you get engaged with the community in Hawaii?  6:30 •    What do you think is going to happen with ctDNA moving forward? 8:29 •    Can you utilize ctDNA and minimal residual disease information to determine how long patients need to be on adjuvant therapy?  11:42 •    How did you get into the ctDNA space?  15:06 •    How do you see AI transforming health care beyond providing patients with more information and taking more ownership of their health?  18:28 •    Can you tell us more about how a second opinion clinic works? How did this type of clinic develop and become part of what you do?  23:17 •    What are some of your predictions as to what will happen in oncology care over the next ten to twenty years?  29:00 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 37:30 •    How to contact Gandara 38:47 •    Thanks for listening 39:10 David Gandara, MD, is a clinician-scientist and lung cancer specialist internationally recognized for his expertise in thoracic cancers, cancer drug development and biomarker development. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Dr. Gandara can be reached via email drgandara@ucdavis.edu.  Disclosures: Jain reports no relevant financial disclosures. Gandara reports institutional research grants from Astex, Amgen and Genentech; institutional consulting for AstraZenica, Exact Sciences, Genentech, Guardant Health, IO Biotech and Oncohost; consulting for Adagene, Henlius USA, Foundation Medicine and Sanofi; serves on the advisory board of Abbvie, Janssen, Merck, Mirati, Regeneron and Revolution Medicine. 

In this episode, host Shikha Jain, MD, speaks with Michel van Harten, MD, about creating better information systems for physicians and patients, how shared decision-making can improve drug development and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About van Harten 0:20 •    The interview 1:00 •    What was your journey to becoming a physician and beyond to where you are now? 1:24 •    How did you learn the necessary skills to be an exceptional leader in this space?  2:51 •    How many years were you a practicing physician for? 3:53 •    What does myTomorrows do, and what drew you to this type of work? 4:54 •    Where is this service available?  7:19 •    Jain and van Harten on the challenges patients face surrounding eligibility for clinical trials.  8:36 •    Where do you see this going down the line?  10:05 •    Has your company looked into how to these services can impact diversifying clinical trial enrollment?  12:04 •    What are some challenges your company has faced?  13:50 •    How quickly do you think growth will accelerate in this space?  15:26 •    How will this work and resource have major impacts on drug development in a more accelerated way than in the past?  16:11 •    From the patient-facing side, have you faced any challenges concerning patients' willingness to be enrolled in clinical trials?  18:22 •    What is next for you, and where do you see yourself in twenty years?  19:13 •    Do you have any concerns about AI in health care? […] What should we be aware of when utilizing AI in this space?  19:45 •    Jain and van Harten on the challenges and setbacks that come from outdated and inaccurate clinical trial databases.  21:35 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 23:50 •    How to contact van Harten 24:28 •    Thanks for listening 25:17 Michel van Harten, MD, is the CEO of myTomorrows. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Michel van Harten can be reached via email michel.vanharten@mytomorrows.com.  Disclosures: Jain and van Harten report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Melody Harris about the evolution of precision medicine, what physicians and companies can do to help patients better understand precision oncology and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Harris 0:20 •    The interview 1:11 •    Tell us about how you ended up in this niche role. 1:32 •    How did you make the decision to move from practicing law to transitioning your career into this space?  3:56 •    Jain and Harris on the “hype” around precision medicine. 7:11 •    What is the central thesis of the work at NeoGenomics? 10:36 •    What do you feel companies need to be doing to make expectations surrounding diagnoses more transparent for patients?  11:49 •    Where do you think this is all going in the future? Where do you think we'll be in another ten or twenty years?  13:30 •    What do you see yourself doing next?  19:04 •    How can companies address the disparities in health care access, especially in underserved areas?  21:06 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 23:32 •    How to contact Harris 24:30 •    Thanks for listening 25:14 Melody Harris serves as chief operations officer and president of informatics at NeoGenomics, a leading oncology testing services company. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Harris can be reached at melody.harris@neogenomics.com.  Disclosures: Jain and Harris report no relevant financial disclosures. 

In this special crossover episode of Oncology Overdrive, we bring you Healio coverage from the 2024 World Conference on Lung Cancer, as well as Healio's top headlines from the meeting. With insights from Benjamin P. Levy, MD, and top headlines from the conference, Meeting Mic is your on-the-go source for highlights, pearls, and perspectives across all specialties. Benjamin P. Levy, MD, discusses key takeaways from the meeting. 0:49 Read the full coverage here: Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard' Source: Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Perioperative nivolumab improves outcomes in resectable NSCLC Source: Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Despite progress, barriers to lung cancer biomarker testing persist Source: Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Disclosures: Jain reports no relevant financial disclosures. Healio could not confirm relevant financial disclosures for Levy at the time of posting.

In this episode, host Shikha Jain, MD, speaks with Alice Chen, MD, about the impact of misinformation and disinformation during elections, the health care issues on the 2024 ballot and more. Content warning: This episode discusses sensitive topics surrounding women's health and reproductive rights. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Chen 0:32 •    The interview 1:38 •    How did you get into the public health and advocacy spaces? 1:58 •    Have you seen an evolution in medical professionals becoming more involved in politics and advocacy?  5:08 •    How has misinformation impacted politics, health care, policy and the election? 7:25 •    As health care workers, how do we address misinformation to help our communities and patients? 10:51 •    Do you feel that health care workers should use social media for this type of advocacy work?  15:26 •    Is there more of a need for health care workers to be doing this work now than it was pre-social media?  18:14 •    Jain and Chen on how discussions around politics have changed in the last decade.  26:05 •    What are the major health care topics being discussed and impacted by this upcoming election? Why is health on the ballot?  28:33 •    Jain and Chen on women's health and why it matters in this election.  30:58 •    What are health care workers doing to promote advocacy?  37:05 •    If you could summarize this episode in one minute, what would you want listeners to take away? 45:36 •    How to contact Chen 46:11 •    Thanks for listening 46:53 Alice T. Chen, MD, is a mom, physician and national leader in public health, physician advocacy and community organizing.  She serves as the co-chair of the board of directors of Health Care Without Harm. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Chen can be reached @atychen on X and on LinkedIn.  Disclosures: Jain and Chen report no relevant financial disclosures.

In this episode, host Shikha Jain, MD, speaks with Amita Patnaik, MD, FRCPC, about providing patient access to breakthrough drug developments, bringing early phase cancer trials to physicians and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Patnaik 0:21 •    The interview 1:23 •    How did you decide to become an oncologist, and how did you end up co-founding the START Center for Cancer Research?  1:32 •    Can you tell me about START's overarching purpose and where you see its need being most fulfilled? […] What do you hope START will accomplish in the next five to ten years?  11:33 •    How successful has START been at including underrepresented patient populations in clinical data? 17:52 •    What are some challenges you've found as you have navigated through founding a company and executing its mission? 21:48 •    What is next for you?  25:21 •    If someone else wanted to create a company like START, what are some tips you would give them?  27:23 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 32:03 •    How to contact Patnaik 34:44 •    Thanks for listening 35:27 Amita Patnaik, MD, FRCPC, is an internationally recognized medical oncologist and the co-founder of the START Center for Cancer Research. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Patnaik can be reached via email amita.patnaik@startresearch.com or via the START website.

In this episode, host Shikha Jain, MD, speaks with Annmarie Ison about developing safe and accurate software, how software can improve health care disparities and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Ison 0:25 •    The interview 1:10 •    Tell me about how you got into this space […] Can you explain what software development is?  1:34 •    What is Elekta and what does the company do?  10:24 •    How do you feel that this type of innovation is transforming cancer care and treating oncology patients? 13:19 •    How is Elekta and its services helping to address health care disparities? 19:32 •    Where do you think AI fits into the bigger picture of the cancer care landscape?  24:53 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 28:29 •    How to contact Ison 30:25 •    Thanks for listening 31:05 Annmarie Ison is head of customer service for the software business line at Elekta. She has over 25 years of experience as a software development professional, specializing in product development and software architecture for information management systems and radiation therapy delivery devices. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Ison can be reached via email annmarie.ison@elekta.com or via LinkedIn.  Disclosures: Jain and Ison report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Brian Fiske about bringing biotech business ideas to fruition, antibody drug conjugate developments and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Fiske 0:21 •    The interview 1:45 •    How did you get to where you are today, and how did you become interested in this specific area of health care?  2:06 •    What is a timeline from start to finish to bringing an innovative idea to fruition?  6:01 •    How long does it take to form an actual company from an idea?  11:20 •    How do you figure out who you need on your team to move an idea forward? 15:11 •    Tell us about your previous positions at biotech companies, and how did they help lead you into your current space? 20:22 •    What excites you about your job? […] Why do you feel the drive and desire to do this type of work?  24:40 •    Where do you see the work at Mythic Therapeutics doing in the next five to ten years for patient care?  26:27 •    How can we work towards making sure this type of innovative work is available and accessible to patients?  29:20 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 31:16 •    How to contact Fiske 32:12 •    Thanks for listening 32:56 Brian Fiske is chief scientific officer and co-founder of Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate therapies for the treatment of a wide range of cancers. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Fiske can be reached via LinkedIn or the Mythic Therapeutics website.   Disclosures: Jain and Fiske report no relevant financial disclosures. 

On this special edition episode, Shikha Jain, MD, with Physicianary's Hansa Bhargava, MD, and Mend the Gap's Dagny Zhu, MD, discuss the evolution of empowering yourself and others and advocacy with a panel of guests.  •    Intro 1:01 •    What does it mean to empower women in medicine, and what are the ways that we can really empower others to achieve the things that they may not see for themselves?  2:39 •    What are some ways in which you have empowered or hope to empower women in medicine? Are there tips or skills that have worked well?  5:43 •    How have you been empowered by others, or have helped others find their voices?  8:38 •    Do you agree that the conversation is changing toward a cultural shift in empowerment for women in health care? 13:53 •    What are some challenges facing advocacy and empowerment? What do you do when your advocacy work is not being received or it is a struggle to speak up for someone?  18:40 •    Emphasizing the importance of communication in advocacy work. 24:00 •    Intro to Physicianary's part 3 on physician burnout and work-life balance. 24:16 •    Thanks for listening 25:00 Vineet Arora, MD, MAPP (NAM), is a Herbert T. Abelson professor of medicine, vice dean of education in the biological sciences division and dean for medical education at the University of Chicago Pritzker School of Medicine. She is also an elected member of the National Academy of Medicine. She is a founding member of the 501c3 Women of Impact and advisor to the Women in Medicine Summit. Jennifer Bepple, MD, MMCi, is a double board-certified physician in urology and informatics. She is a member of the American Telemedicine Association, American Urologic Association and American Medical Informatics Association and holds a certification from the American Board of Telehealth and the American Board of AI in Medicine. Hansa Bhargava, MD, is Healio's chief clinical strategy and innovation officer. Listen to her Healio podcast, Physicianary. Shikha Jain, MD, FACP, is a board-certified hematology and oncology physician. She is a tenured associate professor of medicine in the division of hematology and oncology, the director of communication strategies in medicine and the associate director of oncology communication & digital innovation at the University of Illinois Cancer Center in Chicago.  Mara Schenker, MD, FACS, FAOA, is an orthopedic trauma surgeon at Grady Memorial Hospital. She is double board certified in orthopedic surgery and clinical informatics. She serves as the chief of orthopedics and associate chief medical information officer.  She is an associate professor of orthopedics at Emory University School of Medicine. She serves on multiple boards for medical and digital technology advisory and sits on major national committees for the American Academy of Orthopaedic Surgeons, AAMC, American College of Surgeons and the Orthopaedic Trauma Association. Dagny Zhu, MD, is a cornea, cataract and refractive surgeon and medical director and partner at NVISION Eye Centers in Rowland Heights, CA. She can be reached on X @DZEyeMD. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD.  Disclosures: The hosts and guest report no relevant financial disclosures.

In this special 100th episode, host Shikha Jain, MD, speaks with her father, Krishna Jain, MD, about work-life balance pertaining to private practice, improving a fragmented health care system and more. •    Welcome to another exciting episode of Oncology Overdrive 1:18 •    About Krishna Jain 1:27 •    The interview 2:27 •    How did you end up in the United States? What was your journey to becoming a world-renowned vascular surgeon?  2:44 •    What was it like being a resident back then, especially as someone who came from abroad?  7:30 •    After training, why didn't you go back to India? 10:12 •    Shikha Jain on how her father inspired her passion for research and mentorship.  13:19 •    Why did you choose to go into private practice, and how did you build your practice and become a leader in this space?  15:18 •    The Jains on the importance of being present for and supporting family.  19:16 •    How did your entrepreneurial life start?  23:55 •    What do your limb preservation centers do?  27:33 •    What are some things that need to be done to improve our fragmented health care system?  29:45 •    What led you found the South Asian American Vascular Society?  34:16 •    How did you end up deciding to go to Kalamazoo, MI instead of going back to India? 39:11 •    What are most proud of in your career? 41:28 •    What do you want to share with the next generation of surgeons and physicians? 44:07 •    The Jains on their relationship growing up and now. 45:44 •    If someone could only listen to the last minute of this episode, what would you want them to take away? 47:48 •    How to contact Jain 48:48 •    Thanks for listening 50:43 Krishna Jain, MD, is a vascular surgeon who has been intimately involved in the growth of office based endovascular centers throughout the country since 2007. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Krishna Jain can be reached via email dockrishna1@gmail.com.  Disclosures: Jain reports no relevant financial disclosures. 

In this special throwback episode, Shikha Jain, MD, talks with Olympic champion Kikkan “Kikkanimal” Randall, about how her positive attitude and athlete mentality have helped her navigate a breast cancer diagnosis and treatment, valuable advice for both oncologists and patients and more. •    Intro 1:44 •    About Randall 1:58 •    The interview 3:22 •    Tell us a bit about you. Who are you? How did you get to where you are and how did you decide you wanted to be a part of the U.S. Olympic cross-country ski team? 3:51 •    How were you diagnosed? 6:12 •    How old were you when you first realized that you had this pebble in your breast? 7:33 •    What type of mentality is it that makes you such a phenomenal Olympic athlete that you were able to translate into this taking charge of your health and taking charge of your cancer as you move forward? 9:20 •    What was the best way for you to cope as you felt this loss of control going through your treatment in certain times? 12:09 •    What did you do to prepare for your clinic visits when you were trying to advocate for yourself? 16:17 •    Can you talk more about the video blog you kept during treatment? 17:55 •    How did you navigate the disease with your son? 21:50 •    How long do they recommend for you to wait to try again (to conceive)? Did you have those conversations? 26:17 •    Do you feel like you are mentally approaching this period of your post-cancer care or your post-treatment time? 29:58 •    Randall running a marathon following the completion of her treatment 32:07 •    How did you get involved with Healthy Futures and Fast and Female, and what exactly do they do? 38:08 •    Did the way that you participate in advocacy change after you were diagnosed with cancer? 42:46 •    One thing you wish oncologists knew when they are treating patients with any kind of cancer, and one thing patients should know if they're newly diagnosed? 48:09 •    How to find Randall 50:26 •    Thanks for listening 51:58 Kikkan Randall is an Olympic champion, active mom, cancer fighter and “Get-Activist.”  We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Randall can be reached at kikkan.com.  Disclosures: Jain reports no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Shyam Natarajan, PhD, about machine learning in cancer research and testing, using technological innovation to address disparities in health care trials and more. •    Welcome to another exciting episode of Oncology Overdrive 1:17 •    About Natarajan 1:22 •    The interview 2:10 •    How did you get into the medical technology space?  2:29 •    Can you explain what machine learning means?  4:37 •    How did you end up co-founding Avenda Health?  7:18 •    Do you think that this type of technology is replicable in other disease types as well? […] Where else do you see this being a benefit? 9:53 •    When you think about AI, what are the other applications for this type of technology outside of oncology?  11:24 •    How do you respond to concerns that AI is becoming too sentient or independent?  12:50 •    What are the checkpoints we need to put in place to make sure that biases in AI algorithms do not become the norm?  16:21 •    Do you have ways to predict who would benefit from these types of technology, and can you categorize patients into who is appropriate for trialing these technologies?  19:44 •    Is there a way to utilize this technology to address disparities in health care?  22:04 •    Have you found that there are specific things that make it harder to enroll patients in these particular clinical trials? How do you navigate those? 24:47 •    If you had a crystal ball that could see fifty years into the future, where do you see all of this technology going? 27:28 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 30:56 •    How to contact Natarajan 31:31 •    Thanks for listening 32:22 Shyam Natarajan, PhD, is the co-founder and CEO of Avenda Health, a medtech company focused on improving outcomes for the one in seven men at risk for prostate cancer. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Natarajan can be reached at www.avendahealth.com or via LinkedIn.  Disclosures: Jain and Natarajan report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Komal Jhaveri, MD, about breakthroughs in breast cancer treatment, where the field is evolving with anti-body drug conjugates and more. •    Welcome to another exciting episode of Oncology Overdrive 1:17 •    About Jhaveri 1:21 •    The interview 1:41 •    How did you get into this highly specialized field? […] How did you become a breast oncologist and find yourself at Memorial Sloan Kettering?  2:07 •    As a breast oncologist, what has really excited you in the breast cancer space over the last decade?  5:02 •    What do you think is going to happen in the next five to twenty years? Where do you think breast cancer treatment is going to evolve?  13:44 •    Do you think AI is going to have a big impact on how we treat patients? 17:47 •    If someone could only listen to the last minute of this episode, what would you want them to take away? 19:52 •    How to contact Jhaveri 20:34 •    Thanks for listening 21:32 Komal Jhaveri, MD, is a breast oncologist & early drug development specialist, clinical director of the early drug development service, and section head of the endocrine therapy research program at Memorial Sloan Kettering Cancer Center (MSK). We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Jhaveri can be reached at her office 646-888-5157, or via email jhaverik@mskcc.org.  Disclosures: Jain reports no relevant financial disclosures. Jhaveri reports she is the principal investigator for Genentech's INAVO120 trial at MSK and co-chair globally.

In this episode, host Shikha Jain, MD, speaks with David Cosgrove, MD, about implementing real-world utilization of clinical trials, the importance of diversity in clinical trials and more. •    Welcome to another exciting episode of Oncology Overdrive 1:17 •    About Cosgrove 1:26 •    The interview 2:54 •    How did you make your way from Ireland to Portland, Oregon?  3:18 •    As a fellow GI oncologist, what are you excited about in the cancer research space?  6:13 •    How can we realistically address disparities in cancer care to deliver the latest breakthroughs to patients?  8:54 •    Jain and Cosgrove on the challenges GI cancers experience in terms of delivery of cancer care compared to colleagues in other spaces. 11:22 •    What excites you about what's happening in oncology right now, and where we're going in this space? 13:30 •    How did you end up as medical director at Compass Oncology?  15:15 •    What are you specifically working on now, and where do you hope to see it go in the next five years?  17:25 •    How do we get more patients from different backgrounds into clinical trials, and why is it important that we do that? 19:05 •    Jain and Cosgrove on challenges facing patient guidelines and qualifications for clinical trials. 21:09 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 23:41 •    How to contact Cosgrove 24:45 •    Thanks for listening 25:49 David Cosgrove, MD, serves as the medical director of Compass Oncology in Portland, Oregon, and specializes in general adult oncology with advanced subspecialty expertise in gastrointestinal cancers. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Cosgrove can be reached via email david.cosgrove@usoncology.com.   Disclosures: Jain and Cosgrove report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with MOLLI Surgical co-founder and CEO, Ananth Ravi, about inventing surgical technology to provide better patient care, addressing inequities in surgical tool access and more. •    Welcome to another exciting episode of Oncology Overdrive 1:15 •    About Ravi 1:27 •    The interview 2:10 •    Tell me about how entered this field and how you ended up founding a company that invents surgical instruments.  2:42 •    How did you end up moving from Zambia to Canada?  5:02 •    Tell me more about MOLLI Surgical. How is this precision surgery unique from what is already out there?  6:47 •    What is your background to help you go from ideation to implementation, and how did you take the steps to make your ideas a reality? 10:31 •    How do you address rural and global disparities when it comes to accessing these technologies?  16:12 •    In an ideal world, where would you see this technology being utilized, and are there any other technologies that you think will revolutionize this type of care?  19:32 •    What else excites you about this space? […] How did you find going from the academic space into this role in the business/corporate space?   22:19 •    Jain and Ravi on work-life balance.  25:51 •    What's next for you in the next three to five years?  29:26 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 30:15 •    How to contact Ravi 30:42 •    Thanks for listening 31:39 Ananth Ravi is president, CEO and co-founder of MOLLI Surgical. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Ravi can be reached at www.mollisurgical.com or via email aravi@mollisurgical.com.  Disclosures: Jain reports no relevant financial disclosures. Ravi reports he is president, CEO and co-founder of MOLLI Surgical.

In this episode, host Shikha Jain, MD, speaks with Cyclacel CEO, Spiro Rombotis, MPH, about developing techniques and therapies for drug development, how technology has affected these advancements and more. •    Welcome to another exciting episode of Oncology Overdrive 1:15 •    About Rombotis 1:23 •    The interview 2:21     •    Can you tell us about how you ended up in the biotech and pharma spaces?  2:41 •    How did you transition to the first CEO of Cyclacel, and what has kept you in the same space for over three decades?  4:45 •    Is this how you envisioned your career? How did this vision evolve over the course of your career?  8:53 •    What does Cyclacel do, and can you describe the types of innovation you are doing there? 10:19 •    With all this new and exciting technology in the field, where do you see epigenetics and precision oncology going in the next ten to twenty years?  15:46 •    What are your thoughts on AI in the oncology space?   22:21 •    Jain and Rombotis on checks and balances when it comes to AI use in cancer care and clinical trials.   27:53 •    What's next for you?  30:53 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 36:18 •    How to contact Rombotis 40:25 •    Thanks for listening 40:43 Spiro Rombotis, MPH, is the CEO of Cyclacel. He has over 36 years at three public biotechs and two pharmas. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Rombotis can be reached via email srombotis@cyclacel.com.  Disclosures: Jain reports no relevant financial disclosures. Rombotis reports Cyclacel Ltd employment and stock ownership.

In this episode, host Shikha Jain, MD, speaks with Jennifer Michaelson, PhD, about how to seek out opportunities in the health care industry, making space for diversity in biotech innovation and more. •    Welcome to another exciting episode of Oncology Overdrive 1:15 •    About Michaelson 1:21 •    The interview 2:30     •    Can you tell us about how you ended up in the biotech executive space?  2:47 •    How do people get involved in this type of work?  12:32 •    Tell us about sourcing innovation in biotech, along with the challenges that come with it. 16:46 •    How do you consider patient access when thinking about innovations in the biotech space? 21:15 •    When you think about the challenges facing leadership and diversity in these spaces, how can we create an inclusive culture in the health care space? What have you done to spearhead a culture of DEI?  23:51 •    Jain and Michaelson on organizations infusing DEI concepts into standards of practice and care. 30:58 •    If someone could only listen to the last minute of this episode, what would you want them to take away? 32:16 •    How to contact Michaelson 33:52 •    Thanks for listening 34:23 Jennifer Michaelson, PhD, is chief scientific officer at Cullinan Therapeutics. Michaelson is a biotech executive with 20+ years of industry experience in oncology, immunology, and immune-oncology drug development. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Michaelson can be found on LinkedIn or via email jmichaelson@cullinanoncology.com.  Disclosures: Jain and Michaelson report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Sean Bohen, MD, about how cancer therapies are changing how oncology can be discussed, shifting from clinical to industry work and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Bohen 1:04 •    The interview 1:30     •    Tell us about your journey. How did you become an oncologist, and how did you make the transition into working in the pharmaceutical industry?  1:51 •    How did you end up at Olema Oncology after working with other pharmaceutical companies? What was your decision-making process to focus on the industry part of your career? 3:44 •    Tell us more about what Olema Oncology does and what your role is there. 6:30 •    What do you see coming down the pipeline for breast cancer research and innovation? … What do you think Olema will contribute to that space? 8:58 •    Bohen and Jain on the ways in which new treatments have resulted in shifting conversations around cancer care and patient quality of life.  12:45 •    If someone in fellowship is interested in working in industry, pharmaceuticals or scientific development, what are the most effective ways to get into this space? 18:21 •    Jain and Bohen on changing the mindset and misconceptions around moving between clinical, academic and industry work within the field and after fellowship. 20:52 •    What do you see happening in the oncology landscape twenty years from now?  25:46 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 29:19 •    How to contact Bohen 30:54 •    Thanks for listening 31:52 Sean Bohen, MD, is the President and CEO of Olema Oncology. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Bohen can be reached at olema.com.   Disclosures: Jain and Bohen report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Jonathan D. Licht, MD, about becoming and training qualified leaders in the field, challenges facing health care leaders and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Licht 1:16 •    The interview 3:17     •    Can you tell us about your journey into hematology-oncology and how you ended up where you are today?  3:58 •    How have you found the time and ability to balance and succeed in the research, clinical, translational and leadership parts of your work? 9:05 •    What do you suggest to people who are currently trying to get into leadership positions in their early-to-mid career? 12:52 •    Do you agree with the sentiment that there are some leaders in the field who are put into positions prematurely or are ineffective? As a leader, how do you address the need for further training of future leaders?  18:39 •    What are some of the leadership challenges you have seen in the last several years, and how have you managed to navigate them? 23:20 •    How did you use your leadership skills to navigate the first few years of the pandemic, and how are you continuing to navigate delivery of care post-pandemic? 29:23 •    Tell me about the process of achieving NCI designation and what it means for your institution. 36:25 •    How have you had to navigate state health care legislation and policies challenging reproductive health care?  42:16 •    If someone could only listen to the last minute of this episode, what would you want them to take away? 46:13 •    How to contact Licht 46:56 •    Thanks for listening 48:16 Jonathan D. Licht, MD, is the director of the University of Florida Health Cancer Center.  We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Licht can be reached on X, formerly known as Twitter, @jdlicht or via email jdlicht@ufl.edu.  Disclosures: Jain reports no relevant financial disclosures. Licht reports consultancy for AstraZeneca and research funding for Epizyme.

In this episode, host Shikha Jain, MD, speaks with Aparna Parikh, MD, about cancer and GI malignancies in the global health space, circulating tumor DNA in the field of oncology and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Parikh 1:07 •    The interview 2:08     •    What was your path into medicine, cancer care and GI oncology? 2:35 •    Tell us about what you do in the global health space and what your thoughts are on colon cancer and GI malignancies in the global health space. 8:07 •    Why are we seeing so many more young people being diagnosed with colon cancer in the US and internationally? 12:24 •    Do you think US lifestyle and Western diets compared to the rest of the world have contributed to the rise of early colon cancer diagnoses?  15:04 •    How can physicians talk about lifestyle, diet and environmental/social determinants of health that impact a cancer diagnosis? 17:52 •    Can you provide a brief overview of what is circulating tumor DNA (ctDNA) and liquid biopsy, and how are we using it in this space? 19:44 •    Jain and Parikh on ctDNA as an innovation can be transformative in the field of GI oncology.  24:06 •    What are your predictions for GI oncology in the next ten to twenty years?  26:06 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 28:44 •    How to contact Parikh 30:57 •    Thanks for listening 31:57 Aparna Parikh, MD, is a GI oncologist at the MGH Cancer Center where she directs the colorectal research program and young adults CRC program. She is an associate professor at Harvard Medical School and an international expert in CRC and liquid biopsies. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Parikh can be reached via email aparna.parikh@mgh.harvard.edu. Disclosures: Jain reports no relevant financial disclosures. Parikh reports equity in C2i Genomics XGenomes Cadex and Parithera. Advisor/consultant for Abbvie, AZ, Bayer, Biofidelity, Checkmate Pharmaceuticals, CVS, Delcath, Eli Lilly, FMI, Guardant, Hookipa, Illumina, Inivata, Mirati, Pfizer, Saga, Seagen, Taiho, Scare Inc, Science For America, and Value Analytics Lab. She receives fees from Up to Date.  She has received travel fees from Karkinos Healthcare. She has been on the DSMC for a Roche study and on Steering Committee for Exilixis. She has received research funding to the Institution from BMS, Daiichi Sankyo, Erasca, Genentech, Mirati, Novartis, PMV Pharmaceuticals, Plexxicon, PureTech, Takeda and Syndax. 

In this episode, host Shikha Jain, MD, speaks with Barnaby Balmforth, PhD, about the evolution of genomics in cancer care, the impact of personalized care tools and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Balmforth 1:12 •    The interview 3:01     •    How did you get to where you are today? What drove you to become a leader in this space? 3:45 •    What is genomics, and why is genomic analysis important in cancer care? 7:18 •    Jain and Balmforth on the evolution of technology and challenges facing genomics and diagnostic testing to achieve personalized care for individual patients. 11:59 •    In addition to time, can you speak on the challenge of access for this type of technology?  13:20 •    How have you been able to implement “next day” test results and reports of your technology? 17:50  •    Jain and Balmforth on how Biofidelity's technology can transform the delivery of care, as well as its psychological and mental impact. 19:06 •    What's coming down the line for you and Biofidelity?  20:56 •    What are your thoughts for when you expand beyond thoracic oncology? What are your long-term visions for other disease sites?  24:19 •    Do you have any thoughts on AI and how it may influence genomics in cancer care?  25:51 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 28:37 •    How to contact Balmforth 30:37 •    Thanks for listening 31:10 Barnaby Balmforth, PhD, is co-founder and CEO of Biofidelity. Barnaby has more than 15 years' experience in the leadership of multidisciplinary technology development. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Balmforth can be reached via the Biofidelity website. Disclosures: Jain reports no relevant financial disclosures. Balmforth reports he is an employee of Biofidelity and owns shares in the company.

In this episode, host Shikha Jain, MD, speaks with Christina Gomez, MD, about the power of patients' voices, finding joy in physicians work-life balance and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Gomez 1:09 •    The interview 1:45 •    How did you get to where you are today as a GI oncologist? 2:02 •    Have you seen an increase in young people with GI malignancies, and do you have any thoughts as to why we are seeing this change? 5:23 •    Where did the inspiration for your book, Stopped in My Tracks: A Physician's Collection of Cancer Patients' Quotes, come from? 9:08 •    Jain and Gomez on the power of patient voices. 12:41  •    Thoughts on creating another book?  15:30 •    Where do you see the landscape of oncology going in the age of machine-learning and new technologies? 17:05 •    Jain and Gomez on the different ways physicians can demonstrate personalized care for patients. 21:00 •    What should we do as oncologists and as a society to prevent burnout in health care professionals? 24:00 •    Jain and Gomez on the mindset shift on work-life-balance for physicians. 27:33 •    Jain and Gomez on motherhood and how it can define patient interactions and delivery of care. 29:51 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 34:41 •    How to contact Gomez 36:07 •    Thanks for listening 37:31 Christina Gomez, MD, is a gastrointestinal medical oncologist at Banner MD Anderson Cancer Center.  We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Gomez can be reached at christinagomezmd.com, via Facebook or on Instagram @christygomezmd. Disclosures: Jain and Gomez report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Ashley Sumrall, MD, about advocacy outside of their oncology practices and organizations, what lies ahead for the field of neuro-oncology and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Sumrall 1:16 •    The interview 2:54 •    How did you end up in the neuro-oncology space? 3:21 •    As a neuro-oncologist, how do you stay up-to-date with neurology, oncology and medicine? 7:28 •    Is there a difference in the way you interact with a neuro-oncologist versus a medical oncologist?  8:58 •    What drove you to get into the advocacy space? 10:09 •    Do you predominantly do advocacy work through ASCO, or do you do it through other avenues as well?  12:20 •    If someone is interested in getting involved in becoming an advocate with ASCO, on the local level or on the national level, what is the best way for them to start that process? 15:24 •    How do you talk to people in and outside of organizations about current situations facing health care? 19:40 •    If people are interested in learning more about the AMA or getting involved with an organization like the AMA, how can they do so? 22:31 •    What do you see coming down the pipeline that you think is going to transform the neuro-oncology space? 27:16 •    If someone could only listen to the last minute of this episode, what would you want them to take away? 30:04 •    How to contact Sumrall 32:13 •    Thanks for listening 32:56 Ashley L. Sumrall, MD, is a neuro-oncologist practicing at Levine Cancer Institute in Charlotte, NC.  We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Sumrall can be reached on X, formerly known as Twitter: @AshleySumrallMD.  Disclosures: Jain reports no relevant financial disclosures. Sumrall reports receiving funding from Bristol-Myers Squibb, Exelixis, Kura Oncology, Novocure and Oncoceutics, and being a consultant for Abbvie, Athenex, Bayer, Exelixis and Novocure. 

In this episode, host Shikha Jain, MD, speaks with George Sledge, MD, about patient feedback benefiting leadership decision-making, the future of precision medicine in oncology and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Sledge 1:03 •    The interview 2:59 •    How did you become an oncologist? 3:24 •    Tell us about your journey into leadership in oncology. 5:27 •    Did you continue to see patients while leading organizations?  7:48 •    Jain and Sledge on learning from conversations and experiences with patients. 10:57 •    How did you end up in your previous position as ASCO president?  12:29 •    Do you feel that ASCO is an organization that is adept at adapting to change? 14:37 •    Tell us about Caris Life Sciences and how you pivoted to your role as executive vice president and CMO there. 18:44 •    Where do you see the future of oncology going? 23:00 •    Jain and Sledge on the concerns surrounding artificial intelligence and technology in cancer care and the doctor patient relationship. 26:31 •    What is something aspirational that you think could change the way we deliver cancer care years from now? 31:11 •    If someone could only listen to the last minute of this episode, what would you want them to take away? 35:21 •    How to contact Sledge 36:37 •    Thanks for listening 37:10 George Sledge, MD, serves as executive vice president and chief medical officer at Caris Life Sciences. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Sledge can be reached via email gsledge@carisls.com. Disclosures: Jain reports no relevant financial disclosures. Sledge reports that he has stock options with Syndax.

In this episode, host Shikha Jain, MD, speaks with Jan Kitajewski, PhD, about blending community need with scientific advancement, his role as the director of a cancer care center and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Kitajewski 1:08 •    The interview 2:59 •    Tell me about how you started and your pathway to this position. 3:26 •    You have a very diverse background in various fields of medicine. Was there something that drew you to lead a cancer center? 6:15 •    What are your thoughts on how institutions can shift their mindsets toward setting up research that is more inclusive of patient diversity in clinical trials?  9:44 •    Jain and Kitajewski on The Immortal Life of Henrietta Lacks, mistrust in the health care system, and how institutions can empower their communities. 14:00 •    What does a cancer center director do, and what are some things that people may be surprised to know about your position?  16:30 •    Jain and Kitajewski on the University of Illinois Cancer Center applying for NCI designation, and what the process entails.  22:05 •    Jain and Kitajewski on the challenges and successes that come with physician leadership when making changes at an institution. 29:28 •    What is your vision for the future of the University of Illinois Cancer Center? 34:16 •    If someone could only listen to the last minute of this episode, what would you want them to take away? 40:13 •    How to contact Kitajewski 40:55 •    Thanks for listening 41:35 Jan Kitajewski, PhD, is director of the University of Illinois Cancer Center and a professor and head of the department of physiology and biophysics. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Kitajewski can be reached via email kitaj@uic.edu. Disclosures: Jain reports no relevant financial disclosures. Healio could not confirm relevant financial disclosures for Kitajewski at the time of posting.

In this episode, host Shikha Jain, MD, speaks with Avital O'Glasser, MD, about the challenges facing non-traditional scholarship, amplifying diverse voices in medicine and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About O'Glasser 1:15 •    The interview 2:36 •    Jain and O'Glasser on their friendship and how they met. 2:52 •    What is non-traditional scholarship, and why is it so difficult for academics to adopt to these practices? 5:16 •    Jain and O'Glasser on the added value of non-traditional scholarship in academia and engagement. 11:25 •    How can engaging in non-traditional scholarship be leveraged and disseminated along with more “traditionally” recognized ways of CME? 13:33 •    O'Glasser on Daniel Cabrera's More Than Likes and Tweets: Creating Social Media Portfolios for Academic Promotion and Tenure and Ernest Boyer's The Scholarship of Engagement. 17:19 •    Jain and O'Glasser on utilizing digital abstracts in presenting data and pushing back on non-promotable work.  18:30 •    How can physicians make sure that information reaches its desired audience through non-traditional scholarship, or provide more educational opportunities about this work?  22:29 •    About An Evolution of Empowerment: Voices of Women in Medicine and Their Allies, co-edited by Jain and O'Glasser, and their process in creating this publication. 24:28 •    Do you think we'll collaborate on another book? 32:22 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 35:47 •    How to contact O'Glasser 36:45 •    Thanks for listening 38:08 Avital O'Glasser, MD, FACP, FHM, is a hospitalist and associate professor of medicine at Oregon Health & Science University.  Her clinical practice focus is perioperative medicine, and she is also the assistant program director for social media and scholarship for OHSU's Internal Medicine Residency Program.   We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. O'Glasser can be reached on the Women In Medicine blog. Disclosures: Jain and O'Glasser report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with St. Jude's Steven Gottschalk, MD, and Paulina Velasquez, MD, about the evolution of bone marrow transplant and cell therapy, increasing accessibility to CAR T-cell therapy and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Gottschalk 1:12 •    About Velasquez 1:57 •    The interview 2:23 •    About Gottschalk's journey and how he ended up in this space. 2:56 •    About Velasquez's journey and how she ended up in this space. 4:16 •    Gottschalk on the history of severe combined immune deficiency (SCID), or “bubble boy disease” and his work on developing the cure.  5:04 •    When you think about what we have learned about immunotherapy, immune systems and cancer treatment over the last fifty years, did you think we would be where we are today in cancer care? 7:27 •    How have CAR T-cells transformed health care so far, and what will they do for the future? 8:53 •    What are you currently working on, and what excites you most about that work?  9:57 •    Do you think that we can expect a transformation in CAR T-cells being used in solid tumors in the future? 12:34 •    How do we prioritize enhanced CAR T-cells in clinical studies? 13:38 •    How can we address the challenges facing the delivery of CAR T-cell therapy and make it more accessible to patients? 17:04 •    Where do you see CAR T-cell therapy going in cancer care and in immunodeficiencies? 21:03 •    If you were interviewed again in five years, what do you think you will be doing then, and what do you think we will be talking about? 25:42 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 30:31 •    How to contact Gottschalk and Velasquez 31:22 •    Thanks for listening 31:51 Stephen Gottschalk, MD, St. Jude Department of bone marrow transplantation and cellular therapy chair, focuses his research on cancer immunotherapy, cell therapy and stem cell transplantation. The Gottschalk laboratory focuses on Epstein-Barr virus-specific T cells for treating EBV-associated cancers and using genetically modified T cells for cancer immunotherapy.  Paulina Velasquez, MD, St. Jude Department of bone marrow transplantation and cellular therapy, has made significant contributions to the field of immunotherapy, developing novel T-cell therapy platforms for pediatric hematological malignancies. Her team is pursuing projects that address antigen discovery, tumor immune evasion, persistence and efficacy of CAR T cells and cell-cell interaction within the tumor microenvironment.  We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Gottschalk can be reached via email stephen.gottschalk@stjude.org. Velasquez can be reached via email paulina.velasquez@stjude.org.  Disclosures:  Jain reports no relevant financial disclosures. Gottschalk reports he is co-inventor on patents and patent applications in the fields of cell or gene therapy for cancer, a member of the scientific advisory board of Be Biopharma and CARGO, and the data and safety monitoring board (DSMB) of Immatics and has received honoraria from TESSA Therapeutics. Velasquez reports patent applications in the field of T-cell immunotherapy.

In this episode, host Shikha Jain, MD, speaks with Erica Barnell, MD, PhD, about Geneoscopy's non-invasive screening and early detection technology, helping improve patient compliance for gastrointestinal health and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Barnell 1:07 •    The interview 2:05 •    Tell me about how you got into this space and co-founded your unique company. 2:30 •    How did you find the time to co-find a company on top of completing your PhD program? 4:24 •    Barnell on starting Geneoscopy with her brother and working with family. 5:06 •    What were the steps you took to make the idea of Geneoscopy happen? 6:08 •    Describe the process and technology Geneoscopy is using for early colorectal cancer screening. 7:33 •    What makes your non-invasive screening tests different from others?  9:29 •    Do you have any advice on how to execute a timeline for physicians and scientists who may have ideas like yours? 11:08 •    Jain and Barnell on the advantages of partnering with your network and connections to navigate the challenges of standing up entrepreneurial ventures. 13:36 •    How can physicians find resources outside of their network to help them successfully build a company and execute their ideas? 15:20 •    Tell me more about what Geneoscopy is looking at outside of cancer. 17:40 •    Is this technology something that patients can order directly, and are you thinking of expanding this globally in the future? 19:25 •    What do you envision for Geneoscopy ten years down the line? 20:37 •    Have you received feedback from other physicians? 21:39 •    Jain and Barnell on the positive results of patient compliance with non-invasive screening tests. 23:09 •    What's next for you? Along with growing Geneoscopy, is there anything else that you are working on and passionate about? 24:54 •    Can you talk about how Geneoscopy has focused on equitable access in this space? 27:15 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 29:45 •    How to contact Barnell 30:20 •    Thanks for listening 31:02 Erica Barnell, MD, PhD, is the chief science officer and co-founder of Geneoscopy, a life sciences company focused on transforming gastrointestinal health by empowering patients and providers with innovative tests that help detect, prevent and monitor disease, including colorectal cancer. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Barnell can be reached on X, formerly known as Twitter, @EricaBarnell, or via Geneoscopy's LinkedIn and Facebook and website, geneoscopy.com.  Disclosures:  Jain reports no relevant financial disclosures. Barnell is the CSO and cofounder of Geneoscopy.

In this episode, host Shikha Jain, MD, speaks with Laura Petrillo, MD, about navigating patients through changes and goals in palliative care, understanding patients living with and surviving advanced cancer and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Petrillo 1:03 •    The interview 1:40 •    How did you find yourself in medicine, specifically in palliative care and geriatrics? 2:04 •    How has the evolution of cancer care and technology impacted the way you engage and deliver palliative care? 6:46 •    Jain and Petrillo on the effect changes in palliative care can have on patients. 12:47  •    How do you communicate the distinctions between palliative care and hospice care to patients and physicians? 17:19 •    Do you think that there are ways for people outside of palliative care can incorporate intentional communication with patients in their care? … When should you refer someone to palliative care? 23:45 •    Petrillo and Jain on advanced cancer survivorship and living with advanced cancer.  30:54 •    Jain and Reynolds on the progress made in this space and the road ahead. 29:43 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 36:41 •    How to contact Petrillo 38:30 •    Thanks for listening 38:58 Laura Petrillo, MD, is a palliative care physician-investigator in the Division of Palliative Care and Geriatrics at MGH and an assistant professor of medicine at Harvard Medical School. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Petrillo can be reached on X, formerly known as Twitter, @lpetrillz.  Disclosures:  Jain and Petrillo report no relevant financial disclosures.

In this episode, host Shikha Jain, MD, speaks with Kerry Reynolds, MD, about immunotherapy-related adverse events, creating educational resources on immunotherapy management and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Reynolds 1:06 •    The interview 2:45 •    Tell me about how your journey led you to this field of immunotherapy-related adverse events? 3:12 •    Jain and Reynolds on how immunotherapy has changed how we talk about cancer care. 5:41 •    How did you start the Severe Immunotherapy Complications Service? 6:16 •    When you envision this program, what do you feel are the short-term and long-term goals?  10:47  •    Can you tell me more about how you care for and manage in-patients through your program? 14:34 •    As we learn more, do you think there will ever be a day where all immunotherapy side effects will be able to be managed in the outpatient setting? 16:34 •    How do people get into this clinic, and what types of patients are admitted? 18:35 •    Tell me about your book, Facing Immunotherapy: A Guide for Patients and Their Families. Who is the best audience for this book? 21:35 •    Along with this book, are there other educational resources or initiatives that raise awareness for management of severe immunotherapy complications? 24:56 •    Have you encountered any challenges or obstacles while creating and maintaining educational resources and research initiatives?  27:11 •    Jain and Reynolds on the progress made in this space and the road ahead. 29:43 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 31:10 •    How to contact Reynolds 32:40 •    Thanks for listening 33:27 Kerry Reynolds, MD, is an oncologist at the Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard Medical School. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Reynolds can be reached at MGH SIC, or via email  kreynolds7@partners.org. Disclosures:  Jain reports no relevant financial disclosures. Reynolds reports BMS Institutional research support and is on the advisory board for SAGA Diagnostics.

In this episode, host Shikha Jain, MD, speaks with Amy Comander, MD, about incorporating lifestyle changes for cancer patients, developing lifestyle pathways for survivors and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Comander 1:14 •    The interview 3:40 •    How do you manage to incorporate running on such a high level into your day-to-day life? 4:04 •    Tell us about what lifestyle medicine is and why it is so important to include in patient care? 6:43 •    How do you suggest oncologists who are interested in integrating lifestyle medicine into their treatment plans communicate these changes to their patients? 10:06 •    Jain and Comander on the importance of physical activity in cancer care.  12:09  •    Do you have standard recommendations you give to patients to begin incorporating physical activity and exercise to their treatment plan? 13:34 •    About Comander's patient, and her Walk with Me movement. 16:13 •    How do you incorporate lifestyle health into survivorship discussions after treatment? 17:12 •    Jain and Comander on the evolution of medicine allowing there to be more metrics for holistic care and empowerment for patients. 19:02 •    What types of clinical trials are there for lifestyle medicine? 21:19 •    Comander on The Diet, Exercise, Lifestyles, and Cancer Prognosis Study (DELCaP).  21:45 •    How do you talk to people who may not understand lifestyle medicine or its impact? 23:33 •    Can you talk about the PAVING the Path to Wellness program? 24:54 •    What is the training process for physicians looking to become a lifestyle medicine specialist? 28:40 •    Is there an optimal way to incorporate these specialists in patients' day-to-day without it being a burden for them? 31:11 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 33:13 •    How to contact Comander 34:26 •    Thanks for listening 35:37 Amy Comander, MD, is a breast oncologist at the Massachusetts General Hospital Cancer Center. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Comander can be reached on via the MGH Cancer Center website, on Instagram and Threads @dramycomander or on X, formerly known as Twitter @DrAmyComander. Disclosures:  Jain and Comander report no relevant financial disclosures.

In this episode, host Shikha Jain, MD, speaks with Pia Chowdry, MD, about access to care in rural communities, how physicians can present information to patients and their caregivers and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Chowdry 1:04 •    The interview 1:54 •    What was your journey into oncology and how did you end up practicing in Louisiana? 2:07 •    Can you talk about your work in racial and ethnic disparities, variables in cancer care, and prevention? 4:18 •    Do you feel like being exposed to rural health care settings and challenges has changed the way you practice and talk about care to people outside the area? 6:19 •    How do you navigate enrolling patients in rural areas into clinical trials?  10:35  •    Jain and Chowdry on misconceptions surrounding clinical trial enrollment in rural areas. 12:42 •    What excites you about your job and motivates you to avoid burnout? 13:48 •    Has your experience as a caregiver for patients with cancer affected the ways in which you navigate patients and caregivers through treatment and care? 16:25 •    Jain and Chowdry on the importance of how physicians present themselves to patients and caregivers. 19:39 •    Chowdry and Jain on obstacles facing cancer care in rural areas, as well as benefits. 24:25 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 30:41 •    How to contact Chowdry 31:54 •    Thanks for listening 32:28 Pia Chowdry, MD, is a medical oncologist with LSU Health in New Orleans, LA specializing in genitourinary malignancies. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Chowdry can be reached on X, formerly known as Twitter @Pia_Chowdry, or via email rchow1@lsuhsc.edu. Disclosures:  Jain and Chowdry report no relevant financial disclosures.

In this episode, host Shikha Jain, MD, speaks with Douglas Micalizzi, MD, and Lecia Sequist, MD, about adopting novel technologies for early detection, public perception of prevention screening and more. •    Welcome to another exciting episode of Oncology Overdrive :58 •    About Micalizzi 1:12 •    About Sequist 2:26 •    The interview 4:06 •    Sequist's background and how she got into the screening and prevention area of oncology 4:21 •    Micalizzi on his chemistry background and how he got into this space 8:03 •    About the evolution of early detection and MGH's Cancer Early Detection and Diagnostics Clinic 11:47 •    Who is involved in this clinic and how do you handle a patient's panic over seeing cancer specialists? 14:30 •    Discussion on the New York Times article Not Everything We Call Cancer Should Be Called Cancer and nomenclatures surrounding the various cancer stages and types 19:29 •    Public perception of screening and the “push” from people outside of medicine 28:49 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 36:31 •    How to contact Micalizzi and Sequist 37:51 •    Thanks for listening 39:14 Douglas Micalizzi, MD, is a medical oncologist at Massachusetts General Hospital specializing in breast cancer, early cancer detection and hereditary cancer risk. Lecia V. Sequist, MD, MPH, is currently the Landry Family Professor of Medicine at Harvard Medical School, the Program Director for Cancer Early Detection and Diagnostics at MGH and the leader of the Cancer Risk, Prevention and Early Detection Program at the joint Dana-Farber/Harvard Cancer Center. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Micalizzi and Sequist can be reached through the Massachusetts General Hospital Cancer Early Detection and Diagnostics Clinic webpage. Sequist can also be reached on X, formerly known as Twitter @LeciaSequist.   Disclosures:  Jain and Micalizzi report no relevant financial disclosures. Sequist reports her institution has received funds related to clinical trials from AstraZeneca, Delfi Diagnostics and Novartis.

In this episode, host Shikha Jain, MD, speaks with Mettle Health's Claritza Rios, MD, and Bridget Sumser, SW, about misconceptions surrounding palliative care, communication training as self-care for physicians and more. •    Welcome to another exciting episode of Oncology Overdrive :50 •    About Sumser 1:07 •    About Rios 1:52 •    The interview 2:18 •    About Rios and how she got into palliative care 2:47 •    About Sumser's journey and how she ended up in the palliative care space 4:15 •    How do we approach the stigma of palliative care? How do we handle the misconception of palliative care and how can we change the narrative? 6:47 •    Palliative care and hospice care 15:26 •    Patient hope 24:21 •    Communication training as a form of self-care 28:52  •    Can you tell us about Mettle Health and how people can find you? 31:28 •    Holistic care for patients 33:27 •    Authenticity and being present for patients 36:58 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 43:26 •    How to contact Rios and Sumser 45:52 •    Thanks for listening 47:05 Claritza Rios, MD, is a dedicated physician educator with extensive experience in emergency and internal medicine. Bridget Sumser, SW, became a social worker to help people living with serious illness. Over the course of the last 10 years, she has worked across settings, providing support and companionship to patients, families, community members, and providers. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Sumser can be reached via email bridget@mettlehealth.com. Rios can be reached on Instagram @claritzariosmd. Learn more about Mettle Health by visiting mettlehealth.com.  Disclosures:  Jain reports no relevant financial disclosures. Rios is an MD in Internal Medicine; Emergency Medicine; Hospice and Palliative Medicine. Sumser is a Licensed Clinical Social Worker.

In this episode, host Shikha Jain, MD, speaks with Cardinal Health's Parisa Asgarisabet, PhD and Scott Swain, PhD, MPH about benefits and uses of real-world evidence, the issue of diversity in clinical trials and more. •    Welcome to another exciting episode of Oncology Overdrive 1:11 •    About Swain 1:26 •    About Asgarisabet 2:45 •    The interview 3:30 •    About Swain and how you ended up at Cardinal Health 3:50 •    About Asgarisabet's journey and how she ended up at Cardinal Health 5:09 •    What is Cardinal Health and why should people know about the work they are doing? 6:37 •    How is the work Cardinal Health is doing directly applicable to practicing oncologists?  7:30  •    Jain, Asgarisabet, and Swain on Representation of age, race and ethnicity in real-world evidence (RWE), randomized clinical trial (RCT), and Surveillance, Epidemiology, and End Results (SEER) cancer patient registry data in advanced renal cell carcinoma (aRCC). 10:32 •    How can we scale real world data in a bigger way and make this the standard as opposed to the exception? 14:02  •    Jain and Swain on diversity, equity, and inclusion in the clinical trials design space 17:57 •    Asgarisabet and Swain on the economic implications of a lack of diversity in clinical trials 19:53 •    Swain and Jain on the importance of community engagement and outreach in achieving diversity of backgrounds in clinical trials 24:42 •    What do you think are the next steps to implement real world data in order to make a larger impact? 27:38 •    Should real world data be used in concert with randomized controlled trials or should this data be used independently? 29:02 •    When we talk about these types of transformation in how we look at diseases and deciding the best plan of action, do you anticipate there being a challenge with insurance companies approving treatments using real world data? 30:27 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 35:18 •    How to contact Swain and Asgarisabet 37:57 •    Thanks for listening 39:13 Scott Swain, PhD, MPH is a Director of Regulatory Science and Real-world Evidence with Cardinal Health. Parisa Asgarisabet, PhD is a Lead statistician in the Real-World Evidence & Insights team at Cardinal Health. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on Twitter and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on Twitter: @ShikhaJainMD. Asgarisabet can be reached via LinkedIn or via email parisa.asgarisabet@cardinalhealth.com. Swain can be reached via LinkedIn or via email scott.swain@cardinalhealth.com. Disclosures:  Jain reports no relevant financial disclosures. Asgarisabet and Swain are employees and shareholders of Cardinal Health.

In this episode, hosts Shikha Jain, MD, Douglas H. Jones, MD, Amy Comander, MD, Dagny Zhu, MD, Don Dizon, MD, and Mark A. Lewis, MD, discuss the new social media platform, Threads and how physicians can use it for their practice. •    Welcome to another exciting episode of Oncology Overdrive :57 •    The topic 1:10 •    How many have created a profile on Threads? Why or why not? 2:59 •    Dr. Jain has a Thread profile but is unsure how to get more engagement 3:20 •    Dr. Lewis has convinced coworkers to use social media but has not used Threads yet 4:54 •    Dr. Dizon has a Thread profile but notes that leaving other platforms is leaving those communities and starting all over on a new platform 6:25 •    Giving Threads more time to pick up followers and engagement 11:18  •    Dr. Zhu has a Thread profile and found it easy to create but engagement is not the same as other platforms 12:17 •    Tips and tricks to sharing content on socials, especially Threads 14:33  •    Trouble with other social media platforms 17:55 •    Tips and tricks to building a community on a social media 20:20 •    The power of social media platforms and engagement in established communities 22:30 •    Fighting misinformation 25:13 •    Platforms versus audience 27:15 •    How would you like to see Threads change as a platform? 31:21 •    What is the power of TikTok in terms of getting movement among communities? 33:31 •    How do you create a profile on Threads? 40:30 •    Level of engagement: Twitter vs. Threads 43:31 •    The overwhelming number of platforms 52:29 •    What is the best platform for physicians to use? 53:41 •    Sharable content to post across other platforms 55:34 •    Final thoughts 58:09 •    Thanks for listening 1:02:13 Douglas H. Jones, MD, is the cofounder of Global Food Therapy, cofounder and president of Food Allergy Support Team and director of Rocky Mountain Allergy at Tanner Clinic. You can follow him on Threads @drdouglasjones. Amy Comander, MD, DipABLM, is director of breast oncology and survivorship at the Massachusetts General Hospital Cancer Center in Waltham and at Newton-Wellesley, and medical director of the Massachusetts General Hospital Cancer Center in Waltham. She is director of the Lifestyle Medicine Program at the Massachusetts General Hospital Cancer Center. She is also an instructor in medicine at Harvard Medical School. You can follow her on Threads @dramycomander. Shika Jain, MD, FACP, is an associate professor of medicine with tenure in the division of hematology, oncology and cell therapy at the University of Illinois Cancer Center in Chicago. She is the director of communication strategies in medicine and associate director of oncology communication and digital innovation. She also is consulting editor for Healio Women in Oncology, as well as host of Healio's Oncology Overdrive podcast. You can follow her on Threads @shikajainmd. Dagny Zhu, MD, is a cornea, cataract, and refractive surgeon and medical director and partner at NVISION Eye Centers in Rowland Heights, CA. You can follow her on Threads @dzeyemd. Don S. Dizon, MD, FACP, FASCO, is head of community outreach and engagement at the Cancer Center at Brown University and head of the breast and pelvic malignancies program at Lifespan Cancer Institute. You can follow him on Twitter (X) and TikTok @drdonsdizon. Mark A. Lewis, MD, is the director of gastrointestinal oncology at Intermountain Healthcare in Murray, Utah, and a medical oncologist specializing in cancers of the gastrointestinal tract and accessory organs. You can follow him on Twitter (X) @marklewismd. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on Twitter and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on Twitter: @ShikhaJainMD. Disclosures: The moderators and panelists report no relevant financial disclosures.

In this episode, host Shikha Jain, MD, speaks with the Patient Empowerment Network's Tracy Rode about providing patients with tools for advocacy, developing accessible patient resources and more. •    Welcome to another exciting episode of Oncology Overdrive 1:11 •    About Rode 1:23 •    The interview 2:34 •    Can you tell us about your journey and how you ended up in this space as such a strong voice for patient advocates? 2:52 •    Tell me more about Patient Empowerment Network (PEN), what it does for patients and what it does for health care workers 9:06 •    Jain and Rode on how health care workers can improve ways to communicate information to patients in ways they can absorb 14:03 •    How do you suggest patients and physicians use the resources provided by organizations like PEN? What is the best way to incorporate education into a clinical visit?  19:06  •    Rode and Jain on examples of how much easier it is today for patients to come across misinformation in media, and how organizations can help patients avoid this misinformation 21:50 •    Jain and Rode on patient accessibility and benefits to understanding clinical trials 26:35  •    Can you share how your cancer diagnosis impacted the way you transitioned into thinking about patient advocacy issues and your approach to them? 29:13 •    If someone could only listen to the last two minutes of this episode, what would you want them to take away? 31:35 •    How to contact Rode 34:13 •    Thanks for listening 35:20 Tracy Rode is the executive director of the Patient Empowerment Network (PEN). Rode brings over two decades of non-profit leadership experience, including working with diverse patient populations to improve patient outcomes and increase access to care. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on Twitter and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on Twitter: @ShikhaJainMD. Rode and the Patient Empowerment Network can be reached at powerfulpatients.org, or via LinkedIn, Facebook, and Twitter @power4patients.   Disclosures:  Jain and Rode report no relevant financial disclosures. 

In this episode, host Shikha Jain, MD, speaks with Medidata's Alicia Staley about enhancing the patient care experience from a former patient's perspective, building empathetic technical solutions and more. •    Welcome to another exciting episode of Oncology Overdrive 1:11 •    About Staley 1:22 •    The interview 2:37 •    Tell me about your journey and how you ended up at Medidata with your unique skillset? 2:55 •    Jain and Staley on medical advances in cancer care, and how delivery of that care has not changed 10:36 •    Jain and Staley on the evolution of healthcare as a business and its affects on the doctor-patient relationship 13:27 •    What is Medidata and how you end up doing the work you do as VP there? 15:48  •    How do you translate and communicate emotion into the bottom line in the space that you are in, and how these changes will help others reach their goals? 20:05 •    As a former patient, what are your thoughts on how we can improve clinical trial design?  26:19  •    Staley on the importance of finding examples of organizations that have successfully navigated the important conversations surrounding health care 30:29  •    If you could create your utopia of a health care system, what do you envision it would look like? 31:19 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 34:15 •    How to contact Staley 35:28 •    Thanks for listening 36:21 Alicia Staley has over 20 years of experience in software design and information systems management and is a three-time cancer survivor. At Medidata, Alicia works to infuse the patient perspective throughout the product development lifecycle and help engage patients in novel ways. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on Twitter and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on Twitter: @ShikhaJainMD. Staley can be reached via LinkedIn, or on Twitter @stales.   Disclosures:  Jain reports no relevant financial disclosures. Staley is a full-time employee at Medidata.

In this episode, host Shikha Jain, MD, speaks with Stephen Beeson, MD, about the challenges physicians face when prioritizing work life balance, components for building skills to lead in health care and more. •    Welcome to another exciting episode of Oncology Overdrive 1:11 •    About Beeson 1:23 •    The interview 2:36 •    Tell me about how you got into the coaching and mentorship space. What is it that inspired or motivated you? 3:08 •    Jain and Beeson on empowering physicians to find the joy in their careers while also balancing a family life 9:45 •    What have you found is the biggest challenge that health care workers are facing right now? How do you navigate it? 13:26 •    Jain on the power of community and the importance of mentors 20:23  •    Systemically, how can we make changes to keep physicians in health care on an individual level and on a bigger picture level? 23:41 •    Jain and Beeson on the way we compensate physicians for the invisible workload that helps the health care system 29:20  •    If someone could only listen to the minute of this episode, what would you want them to take away? 34:25 •    How to contact Beeson 34:59 •    Thanks for listening 36:00 Stephen Beeson, MD, is founder and CEO of Practicing Excellence, a nationally recognized speaker, physician and author whose life mission is to coach and develop clinicians to be their best. Learn more about Healio Disruptive Innovators Awards on June 3, 2023 and how to register.  We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on Twitter and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on Twitter: @ShikhaJainMD. Beeson can be reached at practicingexcellence.com, or email stephen@praticingexcellence.com.  Disclosures:  Jain reports no relevant financial disclosures. Beeson is founder and CEO of Practicing Excellence.

In this episode, host Shikha Jain, MD, speaks with Ken Bloom, MD, FCAP, about developing technologies to assist cancer analysis and pathology, the spatial component of antibody conjugates and more. •    Welcome to another exciting episode of Oncology Overdrive 1:11 •    About Bloom 1:16 •    The interview 2:10 •    How did you come into your clinical roles, deciding to become a pathologist and get involved with immunotherapy, and then make the transition into industry? 2:42 •    Bloom on how he got involved with breast cancer pathology and precision medicine 7:29 •    Bloom on his work on developing new mechanisms for revolutionizing digital pathology 9:52 •    How do reference laboratories bring more value to a patient? 15:17 •    Jain and Bloom on the evolution of spatial biology in cancer analysis, sequencing and pathology 18:40 •    Jain on the challenges facing how health care advances in can be communicated to more physicians and oncologists 21:40  •    What are your thoughts on where we're going now with rising excitement for advancements such as AI? 23:24  •    Bloom on Nucleai and how it uses AI to assist in cancer cell analysis 27:56  •    Do you think that over the last three years that technology and our understanding of it has been accelerated because of the ways we have adapted during the pandemic?  30:16  •    Jain and Bloom on the evolution of science and medicine, specifically in oncology, and how health care systems can change to reflect this evolution 38:59 •    If someone could only listen to the minute of this episode, what would you want them to take away? 41:56 •    How to contact Bloom 43:42 •    Thanks for listening 44:37 Ken Bloom, MD, FCAP, is the head of pathology at Nucleai. He brings more than 35 years of clinical experience in pathology, oncology, telemedicine and bioinformatics.  Learn more about Healio Disruptive Innovators Awards on June 3, 2023 and how to register.  We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on Twitter and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on Twitter: @ShikhaJainMD. Bloom can be reached via email ken.bloom@nucleai.ai.  Disclosures:  Jain reports no relevant financial disclosures. Bloom is an employee of Nucleai, a spatial biology company.

In this episode, host Shikha Jain, MD, speaks with Edward Kim, MD about what it means to be a disruptive innovator, how to lead efforts in health care system changes and more. •    Welcome to another exciting episode of Oncology Overdrive 1:11 •    About Kim 1:19 •    The interview 3:00 •    What was your journey into oncology and the leadership roles you hold now? 3:27 •    Jain and Kim on changing specialties in medical school and in careers 10:45 •    Kim on family, his relationship with his daughter, and their viral Taylor Swift concert video  12:34 •    Jain on the upcoming Healio Disruptive Innovators Awards and how to register 17:46 •    What do you think disruptive innovation means? … Why did you agree to join this initiative? 18:07 •    Jain on framing disruptive innovation as a positive within the struggles of the health care system 23:34  •    How can we get our systems and delivery of health care to reflect the innovation that we see in medical technology advances, cancer care advances and other advances now to disrupt things for the future? 25:02  •    Jain and Kim on perceptions of certain treatments, and how it can prevent forward-thinking innovation 31:36  •    Why do we allow ourselves to fall into that trap in health care? … Why have we taken so many years to start addressing these innovations on a larger scale?  32:54  •    Kim and Jain on risk aversion for physicians and how questioning systems has evolved 37:36 •    If someone could only listen to the few minutes of this episode, what would you want them to take away? 43:02 •    How to contact Kim 44:27 •    Thanks for listening 45:10 Edward S. Kim, M.D., M.B.A., FACP, FASCO, is physician-in-chief and senior vice president, City of Hope Orange County, and vice physician-in-chief and professor, City of Hope National Medical Center.  Learn more about  Healio Disruptive Innovators Awards on June 3, 2023, and how to register.  We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on Twitter and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on Twitter: @ShikhaJainMD. Kim can be reached via LinkedIn, Facebook, on Twitter @DrEdKim, or via email edwkim@coh.org.  Disclosures:  Jain reports no relevant financial disclosures. Kim reports affiliation with Boerhinger Ingelheim, Genentech and Mirati.

In this episode, host Shikha Jain, MD, speaks with CureMatch CEO Navid Alipour about the rise of AI in the health care space, how technology can elevate the ways in which we diagnose and deliver health care and more. •    Welcome to another exciting episode of Oncology Overdrive :14 •    About Alipour :28 •    The interview 1:34 •    How did you get into the AI space? 2:06 •    Can you talk about the evolution of AI from before to where we are now?  4:37 •    What are the ways in which you see technologies like CureMatch and CureMetrix having an impact, and what do they do?  9:51 •    Alipour and Jain on utilizing AI in ways that will benefit the patient and help providers deliver better care 17:47 •    Do you think that there's a role for AI and these types of technologies in the space of addressing inequities, providing better care and potentially fixing pervasive issues within the modern-day health care system? 26:52 •    Jain and Alipour on how quickly technology has evolved, and how it can be utilized in health care detection 32:55  •    If someone could only listen to the few minutes of this episode, what would you want them to take away? 38:23 •    Alipour and Jain on the importance of patient advocacy 38:58 •    How to contact Alipour 41:16 •    Thanks for listening 42:54 Navid Alipour is the co-founder and CEO of CureMatch, a company focused on artificial intelligence (AI) technology. He is also a founder of an AI-focused VC fund, Analytics Ventures. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow us on Twitter @HemOncToday and @ShikhaJainMD. Alipour can be reached at curematch.com and curemetrix.com, or on Twitter @CureMatch and @CureMetrix. Disclosures:  Jain reports no relevant financial disclosures. Alipour reports he is the founder of CureMatch.

In this episode, host Shikha Jain, MD, speaks with Jorge García, PharmD, about the economic benefits of biosimilars, the unique perspective pharmacists can bring to cancer care costs and more. •    Welcome to another exciting episode of Oncology Overdrive :14 •    About García :23 •    The interview 2:44 •    How did you enter the world of pharmacy? What was your journey into this field? 3:11 •    Can you tell us about what biosimilars are, and how you found yourself in this space?  5:09 •    What do you think is the next step for biosimilars? 6:34 •    What types of diseases specifically are biosimilars the most exciting for? … What are diseases that biosimilars have the highest impact in? 8:09 •    What is Act4Biosimilars, and what do they do? 12:05 •    How did you get involved with Act4Biosimilars?  13:04  •    Can you expand on what Act4Biosimilars is doing to address inequities and disparities in health care? Is there a way to get biosimilars into the hands of more people who really need it? 14:55 •    How do you see the impact of these initiatives and interventions are going to be over the next few years? 17:14 •    How do you suggest people who are interested in getting involved in this type of work find this path? 19:31  •    Jain and García on his unique perspective of being a pharmacist and having an MBA and understanding cost of care 24:22  •    If you had a crystal ball, and you could see five or ten years from now, what do you hope will have changed in the biosimilar news space? 27:13  •    If someone could only listen to the two minutes of this episode, what would you want them to take away? 30:36 •    How to contact García 31:27 •    Thanks for listening 32:32 Jorge García, PharmD, MS, MHA, MBA, FACHE is the assistant vice president at Baptist Health South Florida, where he is responsible for oncology pharmacy services, non-oncology infusion pharmacy services, and sterile compounding quality. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow us on Twitter @HemOncToday and @ShikhaJainMD. García can be reached via LinkedIn. Disclosures: García and Jain report no relevant financial disclosures.